Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | DRD3 | P35462 | 9/20 | 0.55 |
| ▸ | DRD2 | P14416 | 9/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GOT1 | P17174 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090741 | 0.92 | GAA (0.64) | GAAMAPTDRD3DRD2DRD4 | |
| SCHEMBL7094839 | 0.88 | GAA (0.63) | GAAMAPTDRD3DRD2DRD4 | |
| SCHEMBL7095084 | 0.86 | GAA (0.61) | GAAMAPTDRD3DRD2DRD4 | |
| SCHEMBL7095623 | 0.85 | GAA (0.54) | GAAMAPTDRD3DRD2DRD4 | |
| SCHEMBL7091218 | 0.85 | GAA (0.60) | GAAMAPTDRD3DRD2DRD4 | |
| SCHEMBL7095695 | 0.83 | GAA (0.53) | GAAMAPTDRD3DRD2DRD4 | |
| SCHEMBL7095622 | 0.82 | GAA (0.55) | GAAMAPTDRD3DRD2DRD4 | |
| SCHEMBL7094815 | 0.81 | GAA (0.60) | GAAMAPTDRD3DRD2DRD4 | |
| SCHEMBL7095143 | 0.80 | DRD2 (0.55) | GAAMAPTDRD3DRD2DRD4 | |
| SCHEMBL7094781 | 0.80 | GAA (0.59) | GAAMAPTDRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050307-A1 | Novel indole derivatives | H. LUNDBECK A/S (DK) | 2003-03-13 | — | — | US | claimed |
| US-20030050307-A1 | Novel indole derivatives | H. LUNDBECK A/S (DK) | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050307-A1 | Novel indole derivatives | HTR1A, HTR3C, HTR2C | GAA 4874/4885MAPT 3433/4885DRD3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.